Farah Champsi is a Managing Director at Alta Partners. She currently serves also on the board of directors of Allakos, Chimerix, Kite Pharma, and Trevena. Farah is also responsible for Alta's investments in Achaogen, Cytokinetics, Intarcia and Portola. Previously, she led Alta's investments in Agensys (acquired by Astellas), Esperion (acquired by Pfizer), Excaliard (acquired by Pfizer) and Orphan Medical (acquired by Jazz).
Prior to joining Alta in 2000, Farah was an investment banker at Robertson Stephens & Company where she focused on biotechnology and other life sciences companies. She was elected a General Partner in 1992 and head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street.
She holds a Master of Business Administration from Stanford University and a Bachelor of Arts in Economics from Smith College.